Toggle Nav
  • Menu
  • Setting

DiscoveryProbe™ FDA-approved Drug Library

Catalog No.
1971 FDA-approved drugs
Grouped product items
SizePriceStock Qty
20uL/well(10 mM solution),96 Well Microplates
In stock
100uL/well(10 mM solution),96 Well Deep Well Plate
In stock
100uL/well(10 mM solution),96 Well Racks With Screw Cap
In stock
250uL/well(10 mM solution),96 Well Racks With Screw Cap
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors


DiscoveryProbe™ FDA-approved drug library includes 1971 FDA approved drugs for high throughput screening (HTS) and high content screening (HCS). It can be used to find new targets for old drugs. The bioactivity and safety of these drugs were confirmed by clinical trials. As they are all FDA-approved drugs, the drugs screened can be used for clinical testing directly.

Product Citation

Featured Products of the Library

Catalog No. Product Name Summary Targets CAS Number Smiles
A3298 Cetirizine Antihistamine Neuroscience|Histamine Receptor 83881-51-0 C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
A3789 Salmeterol xinafoate β2-adrenergic receptor agonist GPCR/G protein|Adrenergic Receptor 94749-08-3 C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O.C1=CC=C2C(=C1)C=CC(=C2O)C(=O)O
A4363 Fluvastatin Sodium HMG-CoA reductase inhibitor Metabolism|HMG-CoA Reductase 93957-55-2 CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)[O-])O)O)C3=CC=C(C=C3)F.[Na+]
A4370 Moclobemide (Ro 111163) Reversible inhibitor of MAO-A Metabolism|MAO 71320-77-9 C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl
A8252 Nintedanib(BIBF 1120) VEGFR/PDGFR/FGFR inhibitor Tyrosine Kinase/Adaptors|PDGFR 928326-83-4 CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)NC(=C3C4=C(C=C(C=C4)C(=O)OC)NC3=O)C5=CC=CC=C5
B1792 Montelukast Sodium Leukotriene receptor antagonist GPCR/G protein|CysLT1 receptor 151767-02-1 CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)[O-])O.[Na+]
N1674 Piperine MAPK inhibitor Natural Products 94-62-2 C1CCN(CC1)C(=O)C=CC=CC2=CC3=C(C=C2)OCO3
N1707 Coumarin Precursor in chemical reaction Natural Products 91-64-5 C1=CC=C2C(=C1)C=CC(=O)O2
Download the FDA-approved-drug-library - XLSX       Download the FDA-approved-drug-library - SDF

Quality Control

Related Biological Data


Related Biological Data


Related Biological Data


Related Biological Data


Related Biological Data


Related Biological Data


Related Biological Data


Related Biological Data


Related Biological Data


Related Biological Data


Signaling Pathway

Dopamine Receptor Compare Products
Histamine Receptor Compare Products
HMG-CoA Reductase Compare Products

Storage and Shipping Information

Form Pre-dissolved DMSO solutions Stability Solution: -20°C for 12 months, -80°C for 24 months
Packaging 96-well Microplate format with peelable foil seal and EVA cap (20 μL/well, 10 mM DMSO);
96-well DeepWell format with peelable foil seal and EVA cap (100 μL/well, 10 mM DMSO);
96-well rack with Matrix 2D Barcoded ScrewTop Storage tubes (250 μL or 100 μL/well, 10 mM DMSO).
General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Shipping Condition Evaluation sample solution: ship with blue ice
All other available size: ship with RT, or blue ice upon request


1. Barrows NJ, Campos RK, Powell ST, et al. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host Microbe. 2016 Jul 27. pii: S1931-3128(16)30303-1.
We interrogated a FDA-approved chemicals library for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). In our in vitro screening assay, more than 20 out of 774 tested compounds reduced ZIKV infection. Then these compounds were further validated for inhibition of ZIKV infection in human neural, cervical and placental stem cell lines, as well as primary human amnion cells. We found that others that had no previously known antiviral activity (e.g., daptomycin) and anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) were identified as inhibitors of ZIKV infection. There were several drugs that reduced ZIKV infection across multiple cell types, which could be tested in clinical studies of ZIKV infection and provided small molecules to study ZIKV pathogenesis.
2. Stavrovskaya IG, Narayanan MV, Zhang W, et al. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J Exp Med. 2004 Jul 19;200(2):211-22.
Mitochondria are a major checkpoint in several pathways leading to neuronal cell death and the mitochondrial permeability transition (mPT) may be critical in stroke-related injury. In order to prove this hypothesis, 1,040 FDA-approved drugs and other bioactive compounds were tested as potential mPT inhibitors. We found that 28 structurally related drugs, including tricyclic antipsychotics and antidepressants, capable of delaying the mPT. Clinically achievable doses of promethazine inhibited mPT and were protective in both in vitro and mouse models of stroke. Also, promethazine protected primary neuronal cultures subjected to oxygen-glucose deprivation and reduced neurological impairment and infarct size in mice subjected to middle cerebral artery occlusion/reperfusion. These results provided a class of safe, tolerable drugs for stroke and neurodegeneration and also provided new tools for understanding mitochondrial roles in neuronal cell death.

Compound Library Composition